Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy

Research output: Contribution to journalArticlepeer-review

Standard

Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy. / Yousefnia, Hassan; Radfar, Edalat; Jalilian, Amir Reza; Bahrami-Samani, Ali; Shirvani-Arani, Simindokht; Arbabi, Azim; Ghannadi-Maragheh, Mohammad.

In: Journal of Radioanalytical and Nuclear Chemistry, Vol. 287, No. 1, 01.2011, p. 199-209.

Research output: Contribution to journalArticlepeer-review

Harvard

Yousefnia, H, Radfar, E, Jalilian, AR, Bahrami-Samani, A, Shirvani-Arani, S, Arbabi, A & Ghannadi-Maragheh, M 2011, 'Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy', Journal of Radioanalytical and Nuclear Chemistry, vol. 287, no. 1, pp. 199-209. https://doi.org/10.1007/s10967-010-0676-4

APA

Yousefnia, H., Radfar, E., Jalilian, A. R., Bahrami-Samani, A., Shirvani-Arani, S., Arbabi, A., & Ghannadi-Maragheh, M. (2011). Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy. Journal of Radioanalytical and Nuclear Chemistry, 287(1), 199-209. https://doi.org/10.1007/s10967-010-0676-4

Vancouver

Yousefnia H, Radfar E, Jalilian AR, Bahrami-Samani A, Shirvani-Arani S, Arbabi A et al. Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy. Journal of Radioanalytical and Nuclear Chemistry. 2011 Jan;287(1):199-209. https://doi.org/10.1007/s10967-010-0676-4

Author

Yousefnia, Hassan ; Radfar, Edalat ; Jalilian, Amir Reza ; Bahrami-Samani, Ali ; Shirvani-Arani, Simindokht ; Arbabi, Azim ; Ghannadi-Maragheh, Mohammad. / Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy. In: Journal of Radioanalytical and Nuclear Chemistry. 2011 ; Vol. 287, No. 1. pp. 199-209.

Bibtex

@article{c836da34e4a04cd5a1ce2076188c9dae,
title = "Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy",
abstract = "Rituximab was successively labeled with 177Lu-lutetium chloride. 177Lu chloride was obtained by thermal neutron flux (4 × 1013 n cm-2 s-1) of natural Lu 2O3 sample with a specific activity of 2.6-3 GBq/mg. The macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) was prepared at 25 °C using DOTA, N-hydroxy succinimide (NHS) in CH2Cl2. DOTA-rituximab was obtained by the addition of 1 mL of a rituximab pharmaceutical solution (5 mg/mL, in phosphate buffer, pH 7.8) to a glass tube pre-coated with DOTA-NHS (0.01-0.1 mg) at 25 °C with continuous mild stirring for 15 h. Radiolabeling was performed at 37 °C in 24 h. Radio-thin layer chromatography showed an overall radiochemical purity of >98% at optimized conditions (specific activity = 444 MBq/mg, labeling efficacy; 82%). The final isotonic 177Lu-DOTA-rituximab complex was checked by gel electrophoresis for structure integrity control. Radio-TLC was performed to ensure that only one species was present after filtration through a 0.22 μm filter. Preliminary biodistribution studies in normal rats were carried out to determine complex distribution of the radioimmunoconjugate up to 168 h. The biodistribution data were in accordance with other antiCD20 radioimmunoconjugates already reported.",
keywords = "Lu, Anti-CD20, Biodistribution, DOTA, Radioimmunotherapy",
author = "Hassan Yousefnia and Edalat Radfar and Jalilian, {Amir Reza} and Ali Bahrami-Samani and Simindokht Shirvani-Arani and Azim Arbabi and Mohammad Ghannadi-Maragheh",
note = "Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",
year = "2011",
month = jan,
doi = "10.1007/s10967-010-0676-4",
language = "English",
volume = "287",
pages = "199--209",
journal = "Journal of Radioanalytical and Nuclear Chemistry",
issn = "0236-5731",
publisher = "Akad{\'e}miai Kiad{\'o}",
number = "1",

}

RIS

TY - JOUR

T1 - Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy

AU - Yousefnia, Hassan

AU - Radfar, Edalat

AU - Jalilian, Amir Reza

AU - Bahrami-Samani, Ali

AU - Shirvani-Arani, Simindokht

AU - Arbabi, Azim

AU - Ghannadi-Maragheh, Mohammad

N1 - Copyright: Copyright 2011 Elsevier B.V., All rights reserved.

PY - 2011/1

Y1 - 2011/1

N2 - Rituximab was successively labeled with 177Lu-lutetium chloride. 177Lu chloride was obtained by thermal neutron flux (4 × 1013 n cm-2 s-1) of natural Lu 2O3 sample with a specific activity of 2.6-3 GBq/mg. The macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) was prepared at 25 °C using DOTA, N-hydroxy succinimide (NHS) in CH2Cl2. DOTA-rituximab was obtained by the addition of 1 mL of a rituximab pharmaceutical solution (5 mg/mL, in phosphate buffer, pH 7.8) to a glass tube pre-coated with DOTA-NHS (0.01-0.1 mg) at 25 °C with continuous mild stirring for 15 h. Radiolabeling was performed at 37 °C in 24 h. Radio-thin layer chromatography showed an overall radiochemical purity of >98% at optimized conditions (specific activity = 444 MBq/mg, labeling efficacy; 82%). The final isotonic 177Lu-DOTA-rituximab complex was checked by gel electrophoresis for structure integrity control. Radio-TLC was performed to ensure that only one species was present after filtration through a 0.22 μm filter. Preliminary biodistribution studies in normal rats were carried out to determine complex distribution of the radioimmunoconjugate up to 168 h. The biodistribution data were in accordance with other antiCD20 radioimmunoconjugates already reported.

AB - Rituximab was successively labeled with 177Lu-lutetium chloride. 177Lu chloride was obtained by thermal neutron flux (4 × 1013 n cm-2 s-1) of natural Lu 2O3 sample with a specific activity of 2.6-3 GBq/mg. The macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) was prepared at 25 °C using DOTA, N-hydroxy succinimide (NHS) in CH2Cl2. DOTA-rituximab was obtained by the addition of 1 mL of a rituximab pharmaceutical solution (5 mg/mL, in phosphate buffer, pH 7.8) to a glass tube pre-coated with DOTA-NHS (0.01-0.1 mg) at 25 °C with continuous mild stirring for 15 h. Radiolabeling was performed at 37 °C in 24 h. Radio-thin layer chromatography showed an overall radiochemical purity of >98% at optimized conditions (specific activity = 444 MBq/mg, labeling efficacy; 82%). The final isotonic 177Lu-DOTA-rituximab complex was checked by gel electrophoresis for structure integrity control. Radio-TLC was performed to ensure that only one species was present after filtration through a 0.22 μm filter. Preliminary biodistribution studies in normal rats were carried out to determine complex distribution of the radioimmunoconjugate up to 168 h. The biodistribution data were in accordance with other antiCD20 radioimmunoconjugates already reported.

KW - Lu

KW - Anti-CD20

KW - Biodistribution

KW - DOTA

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=78751612422&partnerID=8YFLogxK

U2 - 10.1007/s10967-010-0676-4

DO - 10.1007/s10967-010-0676-4

M3 - Article

AN - SCOPUS:78751612422

VL - 287

SP - 199

EP - 209

JO - Journal of Radioanalytical and Nuclear Chemistry

JF - Journal of Radioanalytical and Nuclear Chemistry

SN - 0236-5731

IS - 1

ER -